Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT00862784
- Locations
- 🇪🇸
ImClone Investigational Site, Valencia, Spain
Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 266
- Registration Number
- NCT00861094
- Locations
- 🇫🇷
Hopital Du Bocage, Dijon, France
🇫🇷Hopital Ambroise Pare, Boulogne-Billancourt, France
🇫🇷Hopital Saint Andre, Bordeaux, France
Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 268
- Registration Number
- NCT00851084
- Locations
- 🇦🇺
Sanofi-Aventis Investigational Site Number 036001, Hunter Region Mail Centre, Australia
🇩🇪Sanofi-Aventis Investigational Site Number 276001, Hannover, Germany
🇪🇸Sanofi-Aventis Investigational Site Number 724002, Sabadell, Spain
Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
- Conditions
- Interventions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Krankenhaus Nordwest
- Target Recruit Count
- 252
- Registration Number
- NCT00849615
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Beth Israel Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT00831181
- Locations
- 🇺🇸
St. Luke's-Roosevelt Hospital Center - Roosevelt Division, New York, New York, United States
🇺🇸Beth Israel Medical Center - Philipps Ambulatory Care Center, New York, New York, United States
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
- Conditions
- Interventions
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 20
- Registration Number
- NCT00803647
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸CCOP - Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
🇺🇸Edward Hospital, Naperville, Illinois, United States
Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 11
- Registration Number
- NCT00782041
- Locations
- 🇹🇭
Sanofi aventis administrative office, Bangkok, Thailand
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT00778102
Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer
- Conditions
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2008-09-26
- Lead Sponsor
- CONKO-Studiengruppe
- Target Recruit Count
- 92
- Registration Number
- NCT00759226
- Locations
- 🇩🇪
Charite Universitätsmedizin Berlin, Berlin, Germany
Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc
- Conditions
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- University Hospital of Crete
- Target Recruit Count
- 24
- Registration Number
- NCT00755118
- Locations
- 🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷University Hospital of Crete, Dep of Medical Oncology, Heraklion, Crete, Greece
🇬🇷University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.